Cizzle Biotechnology, a spin-out company from the University of York’s Department of Biology, and the Moffitt Cancer Center in America will test patients with suspicious lung nodules as part of the clinical evaluation of Cizzle’s new lung cancer biomarker, CIZ1B.
The biomarker means that there is now the potential for a simple blood test to be used in early detection of lung cancer, reducing the reliance on CT scans, which can often flag non-cancerous nodules, causing undue…
Read More…
Source: https://www.yorkpress.co.uk/news/24622997.cizzle-biotechnology-progresses-cancer-research-tests/